Indication: For the treatment of metastatic malignant melanoma. In addition, DTIC-Dome is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents
Pharmacology: After intravenous administration of DTIC-Dome, the volume of distribution exceeds total body water content suggesting localization in some body tissue, probably the liver. Its disappearance from the plasma is biphasic with initial half-life of 19 minutes and a terminal half-life of 5 hours. 1 In a patient with renal and hepatic dysfunctions, the half-lives were lengthened to 55 minutes and 7.2 hours. 1 The average cumulative excretion of unchanged DTIC in the urine is 40% of the injected dose in 6 hours. 1 DTIC is subject to renal tubular secretion rather than glomerular filtration. At therapeutic concentrations DTIC is not appreciably bound to human plasma protein.
Mechanism Of Action: Possibly blocking the formation of inosinic acid.
Interactions:
DrugBank: Interactions for Dacarbazine
Interactions for Dacarbazine:
No Information Provided.
Chemical IUPAC Name: 5-dimethylaminoazo-3H-imidazole-4-carboxamide
Chemical Formula: C6H10N6O
Half Life: 5 hours
Drug Type: Approved Drug
# Accession No: APRD00331
CAS Registry Number: 3/4/4342
Dacarbazine News (When available)
Genta Completes Marketing Authorization Application to EMEA for ...Jan 3, 2006 Yahoo! News (press release) In this trial, which was conducted at 139 sites in 9 countries, 771 patients were randomly assigned to receive chemotherapy with dacarbazine (DTIC) alone or in ...
Genta Files New Drug Application for FDA Approval of Genasense ...Dec 29, 2005 PharmaLive.com (press release), ...intention to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for the use of Genasense plus dacarbazine in patients ...
SciClone says drug misses trial targets, shares plungeDec 14, 2005 Reuters Zadaxin was, however, found effective in the treatment of malignant melanoma when administered in combination with dacarbazine chemotherapy in a mid-stage trial ...
SciClone melanoma drug looks promisingDec 14, 2005 United Press International The companies are testing a new treatment, Zadaxin, in a large phase 2 trial that is evaluating the drug in combination with dacarbazine chemotherapy with and ...
Techs Fall on Apple's DowngradeDec 14, 2005 123Jump.com, SciClone said it and Sigma-Tau SpA have found from interim results from a Phase 2 trial that Zadaxin with dacarbazine chemotherapy showed a dose-dependent ...
Plenary Session SnapshotDec 19, 2005 Medscape (subscription) ...as discussed in the session, the results of chemo-radiation using a limited number of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine), commonly 4 ...
Patients With Unfavorable Risk Hodgkin’s Lymphoma May Not ...Dec 19, 2005 Cancer Consultants (press release), ...malignancies. ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) is the most commonly used chemotherapy regimen. BEACOPP ...
Patients with Unfavorable Risk Hodgkin’s Lymphoma May Not ...Dec 20, 2005 Cancer Consultants (press release), ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) is the most commonly used chemotherapy regimen for Hodgkin’s lymphoma. ...
PharmaMar Reports Positive Phase II Results on Aplidin(R) in ...Dec 12, 2005 PR Newswire UK (press release), ...of other tumour types, including melanoma, solid tumours and Non-Hodgkin's Lymphoma, both as a single agent and in combination with dacarbazine (DTIC) and ...
Viragen Holds Annual Stockholder Meeting: CEO Issues Progress ...Dec 15, 2005 PR Newswire (press release), ...to expand the approval for Multiferon(R) to include the first-line adjuvant treatment of high-risk malignant melanoma, following dacarbazine (DTIC) after ...
Home
Copyright phasechange.org 2006.
All Rights Reserved.
